Maider Medical Industry Equipment Co (688310) Fair Value & Analysis
Healthcare · CN · Market cap 2.9B CNY
Fair value as of: Jun 24, 2026
Analysis
Maider Medical Industry Equipment Co (688310) currently trades at ¥15.71, while our model-based Fair Value estimate is ¥8.58 — implying the stock looks roughly 45.4% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Maider Medical Industry Equipment Co. Ltd. engages in the research, development, production, sale, and service of intelligent equipment for medical consumables in China and internationally. It offers blood purification solutions, including automatic assembly machine for hemodialyzer, AV fistula needle, peritoneal dialysis, powder barrel, hollow fiber membrane spinning, hemoperfusion cartridge, flushing syringe, and dialysis bloodline catheters, infusion sets, and central venous catheter; and transfusion solutions, such as automatic assembly machine for disposable infusion set. The company also provides biological reagents comprising a PCR automatic packaging product line; tube extrusion and cutting solutions, such as an automatic production machine for medical catheter; blood collection solutions consisting of automatic assembly machine for blood lancet, safety blood collection needle; and injection solutions, including an automatic assembly machine for pre-filled and safety syringe…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Maider Medical Industry Equipment Co (688310) undervalued?
What is the fair value of 688310?
What is the quality score of 688310?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.